Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai Patents (Class 514/183)
  • Patent number: 10689374
    Abstract: Pyrimidine-thiazolidinone derivatives may be used for preventing or treating diseases in humans or animals, and have demonstrated efficacy specifically in treating type-2 diabetes. Methods of synthesizing the pyrimidine-thiazolidinone derivatives, described herein, can provide high yields in a short time and with high purity. The pyrimidine-thiazolidinone derivatives demonstrate improved hypoglycemic activity compared to most anti-diabetic drugs currently available.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: June 23, 2020
    Assignee: United Arab Emirates University
    Inventors: Abdu Adem, Shaikha S. Al Neyadi, Ibrahim M. Abdou, Alaa A. Salem, Naheed Amir
  • Patent number: 10689708
    Abstract: In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: June 23, 2020
    Assignee: CELGENE CORPORATION
    Inventors: Matthew William Burnell Trotter, Alberto Risueno Perez, Michael Pourdehnad, Anita Gandhi, Patrick Hagner
  • Patent number: 10675271
    Abstract: The present invention pertains to specific clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. It also pertains to the use of this clonidine and/or clonidine derivative for the manufacture of a pharmaceutical composition intended to prevent and/or alleviate the adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. This invention is further directed to a kit comprising: (a) a clonidine and/or clonidine derivative, and (b) at least one alkylating chemotherapeutic agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: June 9, 2020
    Assignee: MONOPAR THERAPEUTICS, INC.
    Inventors: Bérangère Vasseur-Demarcy, Pierre Attali
  • Patent number: 10669289
    Abstract: Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmune disorder or hematological malignancies.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: June 2, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Markus Klein, Oliver Schadt, Philipp Haselmayer, Mireille Krier
  • Patent number: 10662191
    Abstract: Derivatives of N,N-diethyl-N?-phenyl-piperazine, a silent agonist of the mammalian ?7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 26, 2020
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC.
    Inventors: Nicole Alana Horenstein, Roger Lee Papke, Marta Quadri
  • Patent number: 10654843
    Abstract: The present disclosure provides compounds that are Large Multifunctional Protease 7 (LMP7) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of LMP7. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: May 19, 2020
    Assignee: Principia Biopharma Inc.
    Inventors: Timothy Owens, Kenneth Albert Brameld
  • Patent number: 10647679
    Abstract: This disclosure relates to tetrahydroisoquinolines, salts, and derivatives useful for managing mental or cognitive diseases or conditions of the brain or central nervous system. In certain embodiments, the disclosure relates to compounds and compositions having formula I: prodrugs, esters, or salts thereof, wherein the substituents are described herein.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: May 12, 2020
    Assignee: Emory University
    Inventors: Katie L. Strong, David Menaldino, Dennis C. Liotta, Stephen F. Traynelis, Rose M. Freel, Matthew Epplin
  • Patent number: 10647699
    Abstract: The present invention relates to compounds of the general formula (I) in which Q, V, T, W, X, Y and A have the meanings given in the description—and to their use for controlling animal pests.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: May 12, 2020
    Assignee: Bayer CropScience Aktiengesellschaft
    Inventors: Johannes-Rudolf Jansen, Markus Heil, Reiner Fischer, David Wilcke, Matthieu Willot, Kerstin Ilg, Sascha Eilmus, Peter Lösel, Wolfram Andersch
  • Patent number: 10603308
    Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: March 31, 2020
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During
  • Patent number: 10597368
    Abstract: The present invention provides, in certain aspects, novel syringolin analogues, In certain embodiments, the compounds of the invention are proteasome inhibitors, In other embodiments, the compounds treat or prevent a cancer such as, but not limited to, leukemia in a subject.
    Type: Grant
    Filed: May 7, 2016
    Date of Patent: March 24, 2020
    Assignee: BROWN UNIVERSITY
    Inventors: Jason K. Sello, Kyle A. Totaro
  • Patent number: 10588907
    Abstract: The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: March 17, 2020
    Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu
  • Patent number: 10583107
    Abstract: A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: March 10, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10568320
    Abstract: The present invention provides novel compositions and methods for using the insect neuromodulator tyramine and/or one or more derivatives thereof delivered to insect populations to control certain aspects of such populations. The amount of tyramine and/or one or more derivatives thereof delivered on a per insect basis is significantly greater than a naturally-occurring amount of tyramine normally found in insects and causes deleterious effects including mortality of certain insect life forms and disruption of the reproductive capacity of others in the population.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: February 25, 2020
    Assignees: The United States of America, as represented by the Secretary of Agriculture, Foresight Science & Technology Inc.
    Inventors: Robert K. Vander Meer, Satya P. Chinta
  • Patent number: 10561460
    Abstract: Apparatus, systems, and methods for achieving thermally-induced renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a thermal element to a renal artery via an intravascular path. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: February 18, 2020
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Andrew Wu, Benjamin J. Clark, Denise Zarins, Erik Thai
  • Patent number: 10561674
    Abstract: The present invention discloses processes for the preparation of phospholipid-enriched dairy products as nutraceuticals for the formulation of functional foods, the processes include the steps of: combining a non-dairy-based PL-containing material, having phosphatidylserine (PS) and/or phosphatidic acid (PA) in the PL-containing material, wherein the PS and/or PA is derived in part from an enzymatically-processed lecithin as a PS-calcium and/or -magnesium salt and/or a PA-calcium and/or-magnesium salt via transphosphatidylation with phospholipase D in the presence of L-serine and a calcium and/or magnesium salt, with water and an oil component to form a paste; removing an excess amount of the water from the paste to form a PL-oil solution; and mixing the PL-oil solution with a dairy component, thereby obtaining a PL-enriched dairy product. Alternatively, the PL-oil solution has a weight-to-weight (w-w) concentration of at least about 0.01% of a residual amount of the water to the PL-containing material.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: February 18, 2020
    Assignee: Lipogen Ltd.
    Inventors: David Rutenberg, Ilan Perry
  • Patent number: 10526341
    Abstract: Described herein are thienopyrimidine compounds of Formula (I), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the thienopyrimidine compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., brain tumors such as DIPGs) in a subject. The invention further provides an embryonic stem cell-based tumor cell model, which can be used for drug screening and disease target identification.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: January 7, 2020
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Viviane Tabar, Kosuke Funato
  • Patent number: 10525009
    Abstract: The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: January 7, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Itzhak E. Lerner, Moshe Flashner-Barak, Erwin v Achthoven, Hans Keegstra, Ruud Smit
  • Patent number: 10493053
    Abstract: The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: December 3, 2019
    Assignees: Currax Pharmaceuticals LLC, ProCom One, Inc.
    Inventors: Susan E. Dubé, Neil B. Kavey
  • Patent number: 10487086
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: November 26, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J. P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • Patent number: 10471152
    Abstract: The present disclosure relates to compositions of an aqueous colloidal dispersion of hydroxypropyl methyl cellulose acetate succinate (HPMCAS), and methods for making such colloidal dispersions.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: November 12, 2019
    Assignee: Capsugel Belgium NV
    Inventors: Jonathan Leonard Cape, Warren Kenyon Miller, Dwayne Thomas Friesen, Hassan Benameur, Maryline Clauzel, David Thomas Vodak
  • Patent number: 10426719
    Abstract: An oral care composition including an enzyme and an anhydrous matrix that at least partially stabilizes the enzyme. The anhydrous matrix includes a source of hydrogen peroxide, an acyl donor, a non-aqueous anhydrous liquid, and a thickener.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: October 1, 2019
    Assignee: Colgate-Palmolive Company
    Inventors: Shaotang Yuan, Guofeng Xu, Jennifer Gronlund, Robert Dicosimo, Sharon Haynie, Mark S. Payne
  • Patent number: 10426784
    Abstract: Compounds of formula (I) defined herein are useful as a dopamine D1 receptor positive allosteric modulators (D1 PAM) and can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, schizophrenia negative symptom, CIAS, Parkinson's disease, Alzheimer's disease, Huntington's disease, depression, ADHD, drug dependency, or the like.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: October 1, 2019
    Assignee: Astellas Pharma Inc.
    Inventors: Shimpei Kawakami, Tomoyoshi Imaizumi, Naoyuki Masuda, Shigeki Kunikawa, Masataka Morita, Junko Yarimizu
  • Patent number: 10428387
    Abstract: Methods for treating chronic myeloid leukemia (CML), e.g., BCR-ABL inhibitor imatinib mesylate (IM)-resistant CML, using combination treatments, e.g., combined treatment with a BCR-ABL inhibitor, e.g., IM, and a MEK inhibitor, e.g., trametinib.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: October 1, 2019
    Assignee: University of Massachusetts
    Inventors: Michael R. Green, Leyuan Ma
  • Patent number: 10414732
    Abstract: The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions, in which aldehyde toxicity is implicated in the pathogenesis, by the administration of small molecule therapeutics acting as a scavenger for toxic aldehydes.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: September 17, 2019
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Amanda Buist, Eden Fucci, Stephen G. Machatha, Osama Suleiman, Kate Wittering
  • Patent number: 10414761
    Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: September 17, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shigemitsu Matsumoto, Yasushi Hattori, Masashi Toyofuku, Shinji Morimoto, Masaki Daini, Takuto Kojima, Tomohiro Kaku, Mitsuhiro Ito
  • Patent number: 10414801
    Abstract: Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: September 17, 2019
    Assignee: The Johns Hopkins University
    Inventors: Jun O. Liu, Jingxin Wang, Zufeng Guo, Wei Li, Shridhar Bhat, Manisha Das
  • Patent number: 10406125
    Abstract: The present invention relates to a combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof, in particular the S-methyl 4-(dimethylamino)-4-methylpent-2-ynethioate or a pharmaceutically acceptable salt thereof, and more particularly the 4-(Dimethylamino)-4-methyl-2-pentynethioic acid S-methyl ester fumarate, and a compound able to increase H2O2 level in cancer cells of a subject, in particular for use for the treatment of cancer in a subject, wherein cancer cells of said subject do not overproduce H2O2 in comparison to a control value and have a level of GSH below 5 nmol for 25000 cells.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: September 10, 2019
    Assignee: ADVANCED BIODESIGN
    Inventors: Ismail Ceylan, Gerry Quash, Mileidys Perez-Alea, Guillaume Martin
  • Patent number: 10406243
    Abstract: A medicinal composition for diseases caused by dyslipidemia and/or autophagy dysfunction, etc., said medicinal composition comprising polyrotaxane that carries bulky substituents introduced, via intracellularly degradable bonds, into both ends of a linear molecule penetrating through plural cyclic molecules.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: September 10, 2019
    Assignee: National University Corporation Tokyo Medical and Dental University
    Inventors: Atsushi Tamura, Nobuhiko Yui
  • Patent number: 10391175
    Abstract: Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: August 27, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Xu Ran, Yujun Zhao, Chao-Yie Yang, Liu Liu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Jennifer Lynn Meagher, Duxin Sun, Xiaoqin Li, Bing Zhou, Hacer Karatas, Ruijuan Luo, Arul Chinnaiyan, Irfan A. Asangani
  • Patent number: 10385034
    Abstract: The present invention describes compounds according to formula I: and compounds according to formula II: and additional related flavonoid compounds, as well as the use of the compounds in methods for the prevention or treatment of IL-17A-mediated disease in a subject.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: August 20, 2019
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Xiaoxia Li, Caini Liu, Jun Qin, Liang Zhu, Koichi Fukuda
  • Patent number: 10377772
    Abstract: The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: August 13, 2019
    Assignee: Oncodesign S.A.
    Inventors: Jan Hoflack, Petra Blom, Olivier Lavergne, Sylvie Gomez
  • Patent number: 10370409
    Abstract: The present disclosure is directed to a novel class of peptide-like oligomers called peptide tertiary amides (PTAs) and a combinatorial library of PTAs along with synthetic routes for the preparation of large combinatorial libraries of these compounds. The peptide tertiary amides provide an exceptional source of high affinity and selective protein ligands that are useful as tools for biological research and as drug leads, among others.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: August 6, 2019
    Assignee: The Scripps Research Institute
    Inventors: Thomas Kodadek, Yu Gao
  • Patent number: 10357500
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: July 23, 2019
    Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Patent number: 10344039
    Abstract: The present invention provides a compound of Formula (I) and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds and said stereoisomers, and pharmaceutical compositions thereof, and methods for using said compounds and compositions for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: July 9, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Yeon-Hee Lim, Jiayi Xu, Wei Zhou
  • Patent number: 10342866
    Abstract: Small molecule integrin ligand mimetics facilitate integrin-ligand interactions, which may be used to prepare vaccines, adoptive cell therapies, immunotherapies for cancer, and a variety of other conditions. As integrin mediated cell-cell interactions are critical to antigen presentation and effector cell killing, increasing the efficiency of integrin receptor-ligand interactions will stabilize the immune synapse and improve effector functions. Compositions and methods including the mimetics enhance: (1) the priming of vaccines (including, but not limited to, cancer vaccines); (2) cytolytic activity of adoptive cell therapies (including, but not limited to ??T-cells, CTLs, NK, iNKT); (3) immunotherapies (including, but not limited to, negative checkpoint blockage strategies such as anti-CTLA-4 and anti-PD-1); and (4) biologic therapies (including, but not limited, to trastuzumab and rituxamab), whereby the mechanism-of-action includes antibody dependent cellular cytotoxicity (ADCC).
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: July 9, 2019
    Assignees: 7 HILLS INTERESTS LLC, TEXAS HEART INSTITUTE
    Inventors: Darren G. Woodside, Peter Vanderslice, Upendra K. Marathi
  • Patent number: 10328150
    Abstract: Dosage forms comprising preparations of slightly water-soluble active substances in a polymer matrix of polyether copolymers, the polyether copolymers being obtained by free radical polymerization of a mixture of from 30 to 80% by weight of N-vinyllactam, from 10 to 50% by weight of vinyl acetate and from 10 to 50% by weight of a polyether, and of at least one slightly water-soluble polymer in which the slightly water-soluble active substance is present in amorphous form in the polymer matrix.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: June 25, 2019
    Assignee: BASF SE
    Inventors: Karl Kolter, Dejan Djuric, Stefan Fischer
  • Patent number: 10292959
    Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: May 21, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 10292389
    Abstract: The disclosure provides a pediculicidal composition comprising a metal chelating agent; a carrier vehicle comprising water and an activating solvent system comprising an alcohol and a hydrocarbon. The carrier vehicle may be in the form of a solution, a cream, an ointment, a foam, a spray, an emulsion or a gel. The disclosure also provides method for use of a pediculicidal composition to treat human head lice and their eggs and methods for controlling head lice infestation.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: May 21, 2019
    Assignee: DR. REDDY'S LABORATORIES, S.A.
    Inventors: Ronald Harding, Lewis David Schulz, Vernon Morrison Bowles
  • Patent number: 10287262
    Abstract: The present invention provides compounds (n-3 PUFA derivatives) of formula (I): that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: May 14, 2019
    Assignees: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, BOARD OF REGENTS OF UNIVERSITY OF TEXAS SYSTEM
    Inventors: Wolf-Hagen Schunck, Gerd Wallukat, Robert Fischer, Cosima Arnold, Dominik N. Mueller, Narender Puli, John R. Falck
  • Patent number: 10273202
    Abstract: Described herein are nitroxyl progenitor compounds, and compositions including, and methods or generating, the compounds thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: April 30, 2019
    Assignee: The Johns Hopkins University
    Inventors: John P. Toscano, Christopher M. Pavlos, Preeya Kapur Boppana
  • Patent number: 10245276
    Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: April 2, 2019
    Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Carlos Ramon Plata Salaman, Nicolas Tesson
  • Patent number: 10238668
    Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: March 26, 2019
    Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Carlos Ramon Plata Salaman, Nicolas Tesson
  • Patent number: 10227610
    Abstract: Methods and compositions for increasing nuclease-mediated genomic modification using DNA repair inhibitors are provided.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: March 12, 2019
    Assignees: Sangamo Therapeutics, Inc., Sigma Aldrich Co LLC
    Inventors: Fuqiang Chen, Qiaohua Kang, Thomas Wechsler
  • Patent number: 10226455
    Abstract: Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: March 12, 2019
    Assignee: The Texas A&M University System
    Inventors: James C. Sacchettini, Matthew W. Miller, Deeann Wallis, Nian E. Zhou, Theresa W. Fossum
  • Patent number: 10213507
    Abstract: The invention pertains to a formulation comprising magnetic nanoparticles (MENPs) conjugated to or mixed with a therapeutic cargo, the therapeutic cargo comprising an HIV inhibitor, an inhibitor of BACE-1 activity or expression, and a cocaine antagonist. In one embodiment, the formulation comprises WA, miR-107, and BD1063. The MENPs conjugated or mixed with the therapeutic cargo can be encapsulated within liposomes. The liposomes can be surface modified with an affinity ligand that targets the liposomes to the brain. The invention also pertains to a method of treating an HIV infection in a subject having cocaine addiction, by administering to the subject the formulation of the invention and applying to the subject magnetic forces to guide the MENPs across the blood brain barrier and into brain parenchyma and releasing the therapeutic cargo into the brain parenchyma by applying to the subject an alternating current.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: February 26, 2019
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Madhavan Nair, Sneham Tiwari, Adriana Yndart Arias
  • Patent number: 10211404
    Abstract: A high-performance organic electroluminescence device and an electronic equipment provided with the organic electroluminescence device are provided. Also, a compound for achieving the organic electroluminescence device and the electronic equipment is provided. Specifically, a compound having a specific structure having a triphenylene skeleton, an organic electroluminescence device using the compound and an electronic equipment provided with the organic electroluminescence device are provided.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: February 19, 2019
    Assignee: IDEMITSU KOSAN CO., LTD.
    Inventors: Masahiro Kawamura, Yumiko Mizuki, Hirokatsu Ito, Tomoharu Hayama, Tasuku Haketa
  • Patent number: 10208002
    Abstract: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: February 19, 2019
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue
  • Patent number: 10189798
    Abstract: The present disclosure pertains to antimicrobial compounds that include silver (Ag) and an s-triazine ring with substitutions at nitrogen or carbon atoms of the s-triazine ring. In one example, the antimicrobial silver s-triazine may be readily incorporated in a variety of compositions and devices in both medical and non-medical settings. In another example, the said compounds may possess broad spectrum antimicrobial activity against bacteria, viruses, fungi and other microbes.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: January 29, 2019
    Assignee: MEDICAL TECHNOLOGY RESEARCH INC
    Inventor: Bhalchandra M. Karandikar
  • Patent number: 10188674
    Abstract: Pharmaceutical compositions adapted for the parenteral administration, including intravenous administration, of triazole containing macrolide antibiotics, and methods for their use in the treatment of bacterial, protozoal, and other infections are described herein.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: January 29, 2019
    Assignee: CEMPRA PHARMACEUTICALS, INC.
    Inventors: David E. Pereira, Sara Wu, Prabhavathi Fernandes
  • Patent number: 10166191
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: January 1, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams